ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 723,31
0,68%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Royaume-Uni
  5. AQSE
  6. HUTCHMED China Limited (HCM.GB)

  7. HUTCHMED China Limited (HCM.GB) Actualités

HCM.GB

HUTCHMED China (HCM.GB)

HUTCHMED China Limited
De:
Trier par:
 Showing the most relevant articles for your search:AQSE:HCM.GB
DateHeureSourceTitreSymboleSociété
29/12/202309h30UK RegulatoryHutchmed (China) Limited Total Voting RightsAQSE:HCM.GBHUTCHMED China Limited
29/12/202309h30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnAQSE:HCM.GBHUTCHMED China Limited
21/12/202311h00UK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementAQSE:HCM.GBHUTCHMED China Limited
09/11/202308h00UK RegulatoryHutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib)AQSE:HCM.GBHUTCHMED China Limited
24/10/202310h30UK RegulatoryHutchmed (China) Limited Vesting of awards under the LTIPAQSE:HCM.GBHUTCHMED China Limited
14/09/202310h30UK RegulatoryHutchmed (China) Limited Director's Share DealingAQSE:HCM.GBHUTCHMED China Limited
21/08/202308h00UK RegulatoryHutchmed (China) Limited Sovleplenib Phase 3 Study Meets Primary EndpointAQSE:HCM.GBHUTCHMED China Limited
07/08/202310h30UK RegulatoryHutchmed (China) Limited Exercise of Share Options by a DirectorAQSE:HCM.GBHUTCHMED China Limited
31/07/202313h00UK RegulatoryHutchmed (China) Limited Interim Results and Business UpdatesAQSE:HCM.GBHUTCHMED China Limited
13/07/202310h30UK RegulatoryHutchmed (China) Limited Changes to Board and Technical CommitteeAQSE:HCM.GBHUTCHMED China Limited
26/06/202310h30UK RegulatoryHutchmed (China) Limited HUTCHMED to Announce 2023 Half-Year ResultsAQSE:HCM.GBHUTCHMED China Limited
16/06/202308h00UK RegulatoryHutchmed (China) Limited Phase III FRESCO-2 Results in The LancetAQSE:HCM.GBHUTCHMED China Limited
15/06/202316h39UK RegulatoryHutchmed (China) Limited MAA of Fruquintinib Validated by the EMAAQSE:HCM.GBHUTCHMED China Limited
06/06/202311h00UK RegulatoryHutchmed (China) Limited LTIP and Share Option SchemeAQSE:HCM.GBHUTCHMED China Limited
26/05/202308h00UK RegulatoryHutchmed (China) Limited Fruquintinib NDA Granted Priority Review by FDAAQSE:HCM.GBHUTCHMED China Limited
17/05/202310h30UK RegulatoryHutchmed (China) Limited Standard form for notification of major holdingsAQSE:HCM.GBHUTCHMED China Limited
12/05/202314h15UK RegulatoryHutchmed (China) Limited Annual General Meeting Poll ResultsAQSE:HCM.GBHUTCHMED China Limited
12/05/202310h30UK RegulatoryHutchmed (China) Limited Board of Directors and Board Committee MembershipAQSE:HCM.GBHUTCHMED China Limited
10/05/202310h30UK RegulatoryHutchmed (China) Limited Appointment of Independent NEDAQSE:HCM.GBHUTCHMED China Limited
11/04/202310h30UK RegulatoryHutchmed (China) Limited 2022 Annual Report and Notice of AGMAQSE:HCM.GBHUTCHMED China Limited
11/04/202310h30UK RegulatoryHutchmed (China) Limited Intended Retirement of Independent NEDAQSE:HCM.GBHUTCHMED China Limited
28/02/202309h30UK RegulatoryHutchmed (China) Limited 2022 Full Year Results and Business UpdatesAQSE:HCM.GBHUTCHMED China Limited
31/01/202309h30UK RegulatoryHutchmed (China) Limited Notice of ResultsAQSE:HCM.GBHUTCHMED China Limited
23/01/202309h00UK RegulatoryHutchmed (China) Limited License to Takeda for Fruquintinib outside ChinaAQSE:HCM.GBHUTCHMED China Limited
18/01/202315h30UK RegulatoryHutchmed (China) Limited Inclusion of ORPATHYS in NRDL in ChinaAQSE:HCM.GBHUTCHMED China Limited
15/11/202208h00UK RegulatoryHutchmed (China) Limited HUTCHMED Announces Strategy UpdateAQSE:HCM.GBHUTCHMED China Limited
14/11/202208h00UK RegulatoryHutchmed (China) Limited Positive Topline Phase 3 Result in FruquintinibAQSE:HCM.GBHUTCHMED China Limited
14/09/202212h00UK RegulatoryHutchmed (China) Limited Share Option Scheme and Long Term Incentive PlanAQSE:HCM.GBHUTCHMED China Limited
08/09/202208h00UK RegulatoryHutchmed (China) Limited FRESCO-2 Colorectal Cancer MRCT Data HighlightsAQSE:HCM.GBHUTCHMED China Limited
23/08/202211h00UK RegulatoryHutchmed (China) Limited Holding(s) in CompanyAQSE:HCM.GBHUTCHMED China Limited
 Showing the most relevant articles for your search:AQSE:HCM.GB

Dernières Valeurs Consultées

TSXV
OPN
LSE
OA09
Citi Fun 25
BIT
UC4YB0
Unicredit Bank
NASDAQ
GKIS
Gold Kist
BOV
NCRI11
Navi Credito Imobiliario...
ASX
AMPLOC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés